Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Achillion Pharmaceuticals, Inc.

 Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against
                       Achillion Pharmaceuticals, Inc.

PR Newswire

NEW YORK, Oct. 17, 2013

NEW YORK, Oct. 17, 2013 /PRNewswire/ -- Bernstein Liebhard LLP today announced
that a class action has been commenced in the United States District Court for
the District of Connecticut on behalf of all those (the "Class") who purchased
securities of Achllion Pharmaceuticals, Inc. ("Achillion" or the "Company")
(NASDAQ: ACHN) between April 21, 2012 and September 27, 2013, inclusive (the
"Class Period").

(Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO)

Achillion is a biopharmaceutical company that discovers and develops solutions
for infectious diseases such as HIV, hepatitis, and resistant bacterial
infections. The Company focuses its research and development on products for
the antiviral and antibacterial markets.

The Complaint alleges that throughout the Class Period, Defendants made false
and/or misleading statements, as well as failed to disclose material adverse
facts about the Company's business, operations, and prospects, including the
safety and suitability of its premier investigative drug for the treatment of
hepatitis, sovaprevir. Defendants failed to inform investors that sovaprevir
in fact did not interact well with other drugs commonly administered to treat
hepatitis and/or HIV. Specifically, the Company misled investors to believe
that even though patients in the Company's clinical trials for sovaprevir had
elevations in liver enzymes, these liver enzymes elevations were transient and
returned to baseline values and were attributable to non-drug-related factors.
As a result of the foregoing, the Company's statements were materially false
and misleading at all relevant times.

On July 1, 2013, the Company disclosed that the FDA instituted a clinical hold
on "sovaprevir after elevations in liver enzymes associated with significantly
higher than anticipated exposures to atazanavir and sovaprevir were noted in a
Phase I healthy subject drug-drug interaction study evaluating the effects of
concomitant administration of sovaprevir with ritonavir-boosted atazanavir."
As a result of this disclosure, Achillion shares declined $2.10 per share or
over 25%, to close at $6.26 per share on July 2, 2013.

Then, on September 27, 2013, after the market closed, the Company disclosed
that the FDA had continued its clinical hold on sovaprevir, after "the FDA
concluded that the removal of the clinical hold is not warranted." As a
result of this disclosure, Achillion shares declined $4.22 per share or over
58%, to close at $3.02 per share on September 30, 2013.

Plaintiffs seek to recover damages on behalf of all Class members who invested
in Achllion securities during the Class Period. If you invested in Achllion
securities as described above during the Class Period, and either lost money
on the transaction or still hold the security, you may wish to join in this
action to serve as lead plaintiff. In order to do so, you must meet certain
requirements set forth in the applicable law and file appropriate papers no
later than December 9, 2013.

A "lead plaintiff" is a representative party that acts on behalf of other
class members in directing the litigation. In order to be appointed lead
plaintiff, the court must determine that the class member's claim is typical
of the claims of other class members, and that the class member will
adequately represent the class. Under certain circumstances, one or more
class members may together serve as lead plaintiff. Your ability to share in
any recovery is not, however, affected by the decision whether or not to serve
as a lead plaintiff. You may retain Bernstein Liebhard LLP, or other counsel
of your choice, to serve as your counsel in this action.

If you are interested in discussing your rights as an Achllion shareholder
and/or have information relating to the matter, please contact Joseph R.
Seidman, Jr. at (877) 779-1414 or seidman@bernlieb.com.

Bernstein Liebhard LLP has pursued hundreds of securities, consumer and
shareholder rights cases and recovered over $3 billion for its clients. It
has been named to The National Law Journal's "Plaintiffs' Hot List" in each of
the last ten years.

You can obtain a copy of the complaint from the clerk of the court for the
United States District Court for the District of Connecticut.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
www.bernlieb.com

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible
for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New
York, New York 10016, (212) 779-1414. The lawyer responsible for this
advertisement in the State of Connecticut is Michael S. Bigin. Prior results
do not guarantee or predict a similar outcome with respect to any future
matter.

Contact Information

Joseph R. Seidman, Jr.
Bernstein Liebhard LLP
http://www.bernlieb.com
(212) 779-1414
seidman@bernlieb.com



SOURCE Bernstein Liebhard LLP

Website: http://www.bernlieb.com/
 
Press spacebar to pause and continue. Press esc to stop.